ご提示いただいた「Figure 3: Framework for pharmacotherapy of depression」の解説テキストに基づいて、治療フェーズ、治療戦略、薬の切り替え、および臨床エビデンスのカテゴリーに分類し、英文のまま整理した表（テーブル）を作成しました。
Fig3-Table 1: Course and Phases of Depression Treatment (A)
| Phase | Demarcation / Transition | Key Clinical Actions & Considerations | Risks on Discontinuation / Withdrawal |
|---|---|---|---|
| Acute | From initiation of treatment to Remission | Discuss potential acute and chronic adverse effects when initiating antidepressants. | N/A (Initiation stage) |
| Continuation | From Remission to Recovery | Maintain treatment to prevent relapse; optimize dosage or monitor tolerability. Jointly with maintenance, should last at least 6–9 months (ideally a year). | Risk of Acute Discontinuation Syndrome (ADS) and relapse. |
| Maintenance | Beyond Recovery | Focus on preventing long-term recurrence. If withdrawing, taper the medication dosage slowly accompanied by structured psychological support. | Risk of recurrence. If symptoms recur and ADS is ruled out, reintroduction of medication may be needed. |
Fig3-Table 2: Pharmacotherapy Strategies: Monotherapy vs. Combination Therapy (B)
| Strategy | Description & Benefits | When Indicated / Practical Considerations | Specific Actions / Examples |
|---|---|---|---|
| Monotherapy | – Preferable approach – Simplifies clinical management – Clearer to identify which agent is responsible for response/adverse effects – Minimizes overall adverse effects | – Standard approach at the beginning of treatment. – Maintained if the patient shows a positive response. – Highly valued by clinicians when switching antidepressants. | Prescribing a single antidepressant agent (e.g., initiating an SSRI). |
| Combination Therapy | – Combines two agents to enhance therapeutic efficacy. – Includes augmentation strategies. | – Only indicated if the first antidepressant ($\text{AD}_1$) has already produced a reasonable partial response. | – Augmenting $\text{AD}_1$ with lithium or atypical antipsychotics (e.g., quetiapine, aripiprazole). – Adding another antidepressant from a different class (e.g., combining mirtazapine with venlafaxine). |
Fig3-Table 3: Antidepressant Switching Strategies (B)
| Reason for Switching | Recommended Strategy | Clinical Reasoning |
|---|---|---|
| Poor Tolerability (Adverse effects) | Within-class switching (e.g., switching to another SSRI) | Attempts to avoid patient-specific adverse effects while maintaining the same general therapeutic mechanism. |
| Inefficacy (Lack of response) | Between-class switching (trialing an altogether different molecule from a different class) | Targets a completely different pharmacological class with a different mechanism of action to achieve a response. |
| General Real-World Trend (over 3 successive switches) | Switching from SSRIs to other classes (e.g., mirtazapine, SNRIs, and tricyclics) | SSRIs remain the most popular first-line option. Mirtazapine use remains steady, while the use of SNRIs and tricyclics gradually increases in successive failed trials. |
Fig3-Table 4: Clinical Evidence & Implications (STAR*D Study)
| Study / Concept | Key Findings on Remission Rate | Clinical Implication / Required Approach |
|---|---|---|
| STAR*D Study (Prospective trial of >4000 patients) | – Original report: 67% cumulative remission rate after up to 4 antidepressant treatment trials. – Recent re-analysis: Suggested the true rate should be 35%. | A substantial number of patients do not respond to pharmacotherapy alone, highlighting the limitations of relying solely on drug trials. |
| Multifaceted Approach | N/A | Underscores the critical need for a comprehensive treatment plan that combines antidepressant treatment with psychological interventions and foundational lifestyle modifications. |
